Pluri (NASDAQ:PLUR) Releases Quarterly Earnings Results, Beats Estimates By $0.12 EPS

Pluri (NASDAQ:PLUR) released its earnings results on Thursday. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.12, FiscalAI reports. The company had revenue of $0.34 million during the quarter, compared to the consensus estimate of $0.66 million.

Pluri Stock Down 5.6%

NASDAQ:PLUR opened at $1.18 on Friday. The firm’s fifty day simple moving average is $1.65 and its 200 day simple moving average is $2.51. The stock has a market cap of $13.15 million, a P/E ratio of -0.26 and a beta of 0.68. Pluri has a twelve month low of $1.18 and a twelve month high of $4.96.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered Pluri from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 26th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Hedge Funds Weigh In On Pluri

An institutional investor recently bought a new position in Pluri stock. Jane Street Group LLC bought a new position in shares of Pluri Inc. (NASDAQ:PLUR) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned 0.14% of Pluri as of its most recent filing with the Securities and Exchange Commission. 16.59% of the stock is owned by institutional investors.

Pluri Company Profile

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.